Comparative Pharmacology
Head-to-head clinical analysis: ADALAT CC versus TIAZAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADALAT CC versus TIAZAC.
ADALAT CC vs TIAZAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, resulting in coronary vasodilation, peripheral vasodilation, decreased myocardial contractility, and decreased AV nodal conduction velocity.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
Oral: 120-360 mg once daily; maximum 540 mg daily.
None Documented
None Documented
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Terminal elimination half-life is 5-7 hours for immediate-release; for TIAZAC (extended-release), effective half-life is approximately 6-9 hours due to prolonged absorption
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
Renal (2-4% unchanged, 60% as inactive metabolites); Fecal (30%); Biliary (minor)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker